ProShare Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.6K | Buy |
+24,129
| New | +$33.3K | ﹤0.01% | 1886 |
|
|
2025
Q2 | – | Sell |
-38,865
| Closed | -$17.6K | – | 2135 |
|
|
2025
Q1 | $17.6K | Sell |
38,865
-2,741
| -7% | -$1.61K | ﹤0.01% | 2045 |
|
|
2024
Q4 | $20.9K | Buy |
41,606
+13,691
| +49% | +$10.1K | ﹤0.01% | 2254 |
|
|
2024
Q3 | $25.3K | Buy |
27,915
+10,141
| +57% | +$9.4K | ﹤0.01% | 2032 |
|
|
2024
Q2 | $17.7K | Sell |
17,774
-6,067
| -25% | -$6.7K | ﹤0.01% | 1813 |
|
|
2024
Q1 | $35.3K | Buy |
23,841
+1,877
| +9% | +$2.13K | ﹤0.01% | 1947 |
|
|
2023
Q4 | $23.9K | Buy |
21,964
+5,198
| +31% | +$5.69K | ﹤0.01% | 1912 |
|
|
2023
Q3 | $19.8K | Sell |
16,766
-18
| -0.1% | -$24 | ﹤0.01% | 1788 |
|
|
2023
Q2 | $23.7K | Buy |
+16,784
| New | +$23.2K | ﹤0.01% | 1829 |
|
|
2022
Q2 | – | Sell |
-23,513
| Closed | -$36K | – | 1974 |
|
|
2022
Q1 | $36K | Sell |
23,513
-3,884
| -14% | -$6.03K | ﹤0.01% | 2138 |
|
|
2021
Q4 | $67K | Buy |
27,397
+11,326
| +70% | +$26.5K | ﹤0.01% | 2249 |
|
|
2021
Q3 | $40K | Sell |
16,071
-15,388
| -49% | -$39.5K | ﹤0.01% | 1973 |
|
|
2021
Q2 | $90K | Buy |
+31,459
| New | +$81.4K | ﹤0.01% | 2306 |
|
|
2020
Q1 | – | Sell |
-14,661
| Closed | -$13K | – | 1398 |
|
|
2019
Q4 | $13K | Buy |
14,661
+2,343
| +19% | +$1.95K | ﹤0.01% | 1784 |
|
|
2019
Q3 | $12K | Buy |
12,318
+359
| +3% | +$372 | ﹤0.01% | 1652 |
|
|
2019
Q2 | $13K | Sell |
11,959
-314
| -3% | -$362 | ﹤0.01% | 1616 |
|
|
2019
Q1 | $16K | Buy |
+12,273
| New | +$15.3K | ﹤0.01% | 1650 |
|
|
2018
Q4 | – | Sell |
-12,522
| Closed | -$26K | – | 1641 |
|
|
2018
Q3 | $26K | Sell |
12,522
-962
| -7% | -$2.02K | ﹤0.01% | 1749 |
|
|
2018
Q2 | $24K | Buy |
13,484
+829
| +7% | +$1.67K | ﹤0.01% | 1785 |
|
|
2018
Q1 | $30K | Sell |
12,655
-2,042
| -14% | -$4.79K | ﹤0.01% | 1698 |
|
|
2017
Q4 | $28K | Buy |
+14,697
| New | +$32.1K | ﹤0.01% | 1787 |
|
|
2017
Q1 | – | Sell |
-12,768
| Closed | -$40K | – | 1614 |
|
|
2016
Q4 | $40K | Buy |
+12,768
| New | +$39.2K | ﹤0.01% | 1719 |
|
|
2015
Q2 | – | Sell |
-12,457
| Closed | -$50K | – | 1722 |
|
|
2015
Q1 | $50K | Sell |
12,457
-1,389
| -10% | -$4.81K | ﹤0.01% | 1869 |
|
|
2014
Q4 | $42K | Sell |
13,846
-11,773
| -46% | -$31.8K | ﹤0.01% | 1926 |
|
|
2014
Q3 | $65K | Sell |
25,619
-5,801
| -18% | -$14K | ﹤0.01% | 2229 |
|
|
2014
Q2 | $77K | Sell |
31,420
-14,907
| -32% | -$33.7K | ﹤0.01% | 2408 |
|
|
2014
Q1 | $123K | Buy |
+46,327
| New | +$136K | ﹤0.01% | 2651 |
|
|
2013
Q4 | – | Sell |
-28,904
| Closed | -$89K | – | 1616 |
|
|
2013
Q3 | $89K | Buy |
28,904
+1,623
| +6% | +$5.14K | ﹤0.01% | 2442 |
|
|
2013
Q2 | $87K | Buy |
+27,281
| New | +$87.4K | ﹤0.01% | 2285 |
|
Other funds holding LCTX
BC
DC
RA
ProShare Advisors's LCTX Position: Q2 2026 in Review
ProShare Advisors opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 24,129 shares worth $31.6K. The stake represents ﹤0.01% of the portfolio and ranks #1886 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in LCTX as recently as Q1 2025.
ProShare Advisors first reported a position in LCTX in Q2 2013 and has held it in 29 quarters since. The position peaked at $123K in Q1 2014. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- ProShare Advisors held 24,129 shares of Lineage Cell Therapeutics worth $31.6K as of Q2 2026.
- Lineage Cell Therapeutics was a new ProShare Advisors position in Q2 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1886 holding.
- ProShare Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 29 quarters since.
- ProShare Advisors's Lineage Cell Therapeutics position peaked at $123K in Q1 2014.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.